· Event impact
Eli Lilly Raises 2026 Guidance to $82-85B on Mounjaro/Zepbound Growth
Type: earningsConfidence: 0.95Verified: keep
Transmission path
Earnings-driven valuation expansion via upward revision of long-term cash flow projections in the GLP-1 category.
Market mechanism
Earnings-driven valuation expansion via upward revision of long-term cash flow projections in the GLP-1 category.
Extended read
The guidance hike to $82-85B cements Eli Lilly's position as the dominant player in the metabolic health space. The primary constraint remains supply rather than demand, as evidenced by the rapid uptake of Zepbound. Investors are now looking at the sustainability of these growth rates as competitors enter the market in late 2026.
Exposed assets
LLY
Continuous event tracking, options routing, and portfolio overlap for this event and the assumptions it moves live inside Market Ontology. Start a trial →